Actualización del diagnóstico y tratamiento de la enfermedad de Crohn

Van Assche, 2010, The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis, J Crohns Colitis, 4, 7, 10.1016/j.crohns.2009.12.003 Burgmann, 2006, The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome?, Clin Gastroenterol Hepatol, 4, 614, 10.1016/j.cgh.2006.03.003 Pimentel, 2000, Identification of a prodromal period in Crohn's disease but not ulcerative colitis, Am J Gastroenterol, 95, 3458, 10.1111/j.1572-0241.2000.03361.x Rothfuss, 2006, Extraintestinal manifestations and complications in inflammatory bowel diseases, World J Gastroenterol, 12, 4819, 10.3748/wjg.v12.i30.4819 Lennard-Jones, 1997, Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group, Eur J Gastroenterol Hepatol, 9, 353, 10.1097/00042737-199704000-00007 Nahon, 2002, Colonoscopy accurately predicts the anatomical severity of colonic Crohn's disease attacks: correlation with findings from colectomy specimens, Am J Gastroenterol, 97, 3102, 10.1111/j.1572-0241.2002.07106.x Schumacher, 1994, A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Histologic course during the 1st year after presentation, Scand J Gastroenterol, 29, 318, 10.3109/00365529409094843 Panes, 2011, Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn›s disease, Aliment Pharmacol Ther, 34, 125, 10.1111/j.1365-2036.2011.04710.x Silverberg, 2005, Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology, Can J Gastroenterol, 19, 5A, 10.1155/2005/269076 Jones, 2008, Relationships between disease activity and serum and fecal biomarkers in patients with Crohn›s disease, Clin Gastroenterol Hepatol, 6, 1218, 10.1016/j.cgh.2008.06.010 Sipponen, 2008, Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn›s disease and histological findings, Aliment Pharmacol Ther, 28, 1221, 10.1111/j.1365-2036.2008.03835.x Sipponen, 2008, Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn›s disease, Inflamm Bowel Dis, 14, 1392, 10.1002/ibd.20490 Sipponen, 2008, Crohn›s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn›s disease activity index and endoscopic findings, Inflamm Bowel Dis, 14, 40, 10.1002/ibd.20312 Hanauer, 2004, Oral Pentasa in the treatment of active Crohn›s disease: A meta-analysis of double-blind, placebo-controlled trials, Clin Gastroenterol Hepatol, 2, 379, 10.1016/S1542-3565(04)00122-3 Dignass, 2010, The second European evidence-based Consensus on the diagnosis and management of Crohn›s disease: Current management, J Crohns Colitis, 4, 28, 10.1016/j.crohns.2009.12.002 Summers, 1979, National Cooperative Crohn›s Disease Study: results of drug treatment, Gastroenterology, 77, 847, 10.1016/0016-5085(79)90385-8 Malchow, 1984, European Cooperative Crohn›s Disease Study (ECCDS): results of drug treatment, Gastroenterology, 86, 249, 10.1016/0016-5085(84)90409-8 Seow, 2008, Budesonide for induction of remission in Crohn›s disease, Cochrane Database Syst Rev, 10.1002/14651858.CD000296.pub3 Steinhart, 2003, Corticosteroids for maintenance of remission in Crohn›s disease, Cochrane Database Syst Rev, 10.1002/14651858.CD000301 Otley, 2005, Budesonide for induction of remission in Crohn›s disease, Cochrane Database Syst Rev, 10.1002/14651858.CD000296.pub2 Sandborn, 2000, Azathioprine or 6-mercaptopurine for inducing remission of Crohn›s disease, Cochrane Database Syst Rev Prefontaine, 2009, Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn›s disease, Cochrane Database Syst Rev Markowitz, 1990, Long-term 6-mercaptopurine treatment in adolescents with Crohn›s disease, Gastroenterology, 99, 1347, 10.1016/0016-5085(90)91160-8 Panes, 2013, Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn›s disease, Gastroenterology, 145, 766, 10.1053/j.gastro.2013.06.009 Cosnes, 2013, Early administration of azathioprine vs conventional management of Crohn›s Disease: a randomized controlled trial, Gastroenterology, 145, 758, 10.1053/j.gastro.2013.04.048 Chaparro, 2013, Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients, Inflamm Bowel Dis, 19, 1404, 10.1097/MIB.0b013e318281f28f Feagan, 2000, A comparison of methotrexate with placebo for the maintenance of remission in Crohn›s disease. North American Crohn›s Study Group Investigators, N Engl J Med, 342, 1627, 10.1056/NEJM200006013422202 Arora, 1999, Methotrexate in Crohn›s disease: results of a randomized, double-blind, placebo-controlled trial, Hepatogastroenterology, 46, 1724 Gomollon F, Rubio S, Charro M, García-López S, Muñooz F, Gisbert JP, et al. [Reccomendations of the Spanish Working Group on Crohn›s Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease]. Gastroenterol Hepatol. 2015;38:24-30. Fraser, 2003, Methotrexate: first-line or second-line immunomodulator?, Eur J Gastroenterol Hepatol, 15, 225, 10.1097/00042737-200303000-00003 van der Woude, 2015, The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease, J Crohns Colitis, 9, 107, 10.1093/ecco-jcc/jju006 Hanauer, 2002, Maintenance infliximab for Crohn›s disease: the ACCENT I randomised trial, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4 Hanauer, 2006, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn›s disease: the CLASSIC-I trial, Gastroenterology, 130, 323, 10.1053/j.gastro.2005.11.030 Sandborn, 2007, Adalimumab for maintenance treatment of Crohn›s disease: results of the CLASSIC II trial, Gut, 56, 1232, 10.1136/gut.2006.106781 Peyrin-Biroulet, 2008, Efficacy and safety of tumor necrosis factor antagonists in Crohn›s disease: meta-analysis of placebo-controlled trials, Clin Gastroenterol Hepatol, 6, 644, 10.1016/j.cgh.2008.03.014 D›Haens, 2008, Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn›s disease: an open randomised trial, Lancet, 371, 660, 10.1016/S0140-6736(08)60304-9 Colombel, 2004, The safety profile of infliximab in patients with Crohn›s disease: the Mayo clinic experience in 500 patients, Gastroenterology, 126, 19, 10.1053/j.gastro.2003.10.047 Keane, 2001, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent, N Engl J Med, 345, 1098, 10.1056/NEJMoa011110 Sandborn, 2013, Vedolizumab as induction and maintenance therapy for Crohn›s disease, N Engl J Med, 369, 711, 10.1056/NEJMoa1215739 Feagan, 2013, Vedolizumab as induction and maintenance therapy for ulcerative colitis, N Engl J Med, 369, 699, 10.1056/NEJMoa1215734 Sands, 2014, Effects of vedolizumab induction therapy for patients with Crohn›s disease in whom tumor necrosis factor antagonist treatment failed, Gastroenterology, 147, 618, 10.1053/j.gastro.2014.05.008 Pearson, 1995, Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis, Ann Intern Med, 123, 132, 10.7326/0003-4819-123-2-199507150-00009 Sands, 2004, Infliximab maintenance therapy for fistulizing Crohn›s disease, N Engl J Med, 350, 876, 10.1056/NEJMoa030815 Colombel, 2009, Adalimumab for the treatment of fistulas in patients with Crohn›s disease, Gut, 58, 940, 10.1136/gut.2008.159251 Van Assche, 2010, The second European evidence-based Consensus on the diagnosis and management of Crohn›s disease: Special situations, J Crohns Colitis, 4, 63, 10.1016/j.crohns.2009.09.009 Tougeron, 2009, Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn›s disease, Dig Dis Sci, 54, 1746, 10.1007/s10620-008-0545-y Rutgeerts, 1995, Controlled trial of metronidazole treatment for prevention of Crohn›s recurrence after ileal resection, Gastroenterology, 108, 1617, 10.1016/0016-5085(95)90121-3 Rutgeerts, 2005, Ornidazole for prophylaxis of postoperative Crohn›s disease recurrence: a randomized, double-blind, placebo-controlled trial, Gastroenterology, 128, 856, 10.1053/j.gastro.2005.01.010 Peyrin-Biroulet, 2009, Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn›s disease: a meta-analysis, Am J Gastroenterol, 104, 2089, 10.1038/ajg.2009.301 Regueiro, 2009, Infliximab prevents Crohn›s disease recurrence after ileal resection, Gastroenterology, 136, 441, 10.1053/j.gastro.2008.10.051 Gisbert, 2009, Loss of response and requirement of infliximab dose intensification in Crohn›s disease: a review, Am J Gastroenterol, 104, 760, 10.1038/ajg.2008.88 Chaparro, 2011, Long-term durability of infliximab treatment in Crohn›s disease and efficacy of dose “escalation” in patients losing response, J Clin Gastroenterol, 45, 113, 10.1097/MCG.0b013e3181ebaef9 Chaparro, 2012, Long-term durability of response to adalimumab in Crohn›s disease, Inflamm Bowel Dis, 18, 685, 10.1002/ibd.21758 Sandborn, 2007, Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial, Ann Intern Med, 146, 829, 10.7326/0003-4819-146-12-200706190-00159 Chaparro, 2012, Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease, Aliment Pharmacol Ther, 35, 971